BioNTech (22UA) Stock Overview
Engages in the development and commercialization of immunotherapies in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
22UA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
BioNTech SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$73.05 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.59 |
| 1 Month Change | 4.24% |
| 3 Month Change | -8.83% |
| 1 Year Change | -6.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22UA | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 2.2% | 2.8% | 1.8% |
| 1Y | -6.3% | 39.6% | 17.5% |
Return vs Industry: 22UA underperformed the Swiss Biotechs industry which returned 41.3% over the past year.
Return vs Market: 22UA underperformed the Swiss Market which returned 17.1% over the past year.
Price Volatility
| 22UA volatility | |
|---|---|
| 22UA Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.3% |
Stable Share Price: 22UA's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: 22UA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7,807 | Ugur Sahin | www.biontech.de |
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
BioNTech SE Fundamentals Summary
| 22UA fundamental statistics | |
|---|---|
| Market cap | CHF 18.35b |
| Earnings (TTM) | -CHF 1.05b |
| Revenue (TTM) | CHF 2.66b |
Is 22UA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22UA income statement (TTM) | |
|---|---|
| Revenue | €2.87b |
| Cost of Revenue | €611.30m |
| Gross Profit | €2.26b |
| Other Expenses | €3.39b |
| Earnings | -€1.14b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 05, 2026
| Earnings per share (EPS) | -4.49 |
| Gross Margin | 78.70% |
| Net Profit Margin | -39.59% |
| Debt/Equity Ratio | 0.2% |
How did 22UA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 05:23 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNTech SE is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Harry Gillis | Berenberg |
| Samuel England | Berenberg |